Literature DB >> 11377352

Analysis of indications for surgical closure of subarterial ventricular septal defect without associated aortic cusp prolapse and aortic regurgitation.

K Lun1, H Li, M P Leung, A K Chau, T Yung, C S Chiu, Y Cheung.   

Abstract

Subarterial ventricular septal defect (VSD) is relatively common in Orientals. We reviewed the outcome of 214 patients (137 males) who were followed for 8.6 +/- 5.2 years (range 0.1 to 24.3) and addressed the issue regarding the necessity and optimum timing of closing subarterial defects before development of aortic valve deformities. Demographic data, transthoracic and transesophageal echocardiographic findings, cardiac catheterization results, and operative findings were reviewed. Kaplan-Meier actuarial analysis was performed to assess the development of aortic valve complications over time. Seventy-five patients with heart failure and pulmonary hypertension underwent surgical closure of VSD at the age of 2.4 +/- 2.9 years. No patient had aortic cusp prolapse before operation and none developed aortic cusp prolapse or aortic regurgitation (AR) on follow-up. In contrast, of the 139 asymptomatic patients managed conservatively, 102 (73%) developed aortic cusp prolapse, 78% of whom (80 of 102) developed AR. The prevalence of aortic cusp prolapse and AR at 1, 5, 10, and 15 years old was 8%, 30%, 64%, and 83%, and 3%, 24%, 45%, and 64%, respectively. Significant prolapse or AR prompted surgical closure of VSD with (n = 22) or without (n = 26) valvoplasty in 48 of 102 patients (47%). The size of the VSD was significantly larger in patients with heart failure (9.6 +/- 3.3 mm) or aortic cusp prolapse (11.7 +/- 4.1 mm) compared with those without heart failure (4.5 +/- 1.4 mm, p <0.001). All patients with aortic cusp prolapse and all but 1 with heart failure had a defect size of > or =5 mm. In conclusion, subarterial VSD of > or =5 mm should be closed as early as possible to prevent development of aortic cusp prolapse and AR. Asymptomatic patients with small defects <5 mm could be managed conservatively.

Entities:  

Mesh:

Year:  2001        PMID: 11377352     DOI: 10.1016/s0002-9149(01)01517-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Eisenmenger ventricular septal defect: classification, morphology, and indications for surgery.

Authors:  Huiwen Chen; Zhiwei Xu; Shunmin Wang; Jia Shen; Zhifang Zhang; Haifa Hong
Journal:  Pediatr Cardiol       Date:  2010-11-17       Impact factor: 1.655

2.  Ruptured sinus of Valsalva aneurysm in two patients with subarterial ventricular septal defect.

Authors:  Ulrike Doll; U Herberg; K Tiemann; J Schirrmeister; C Bernhardt; W Köhler; C Schmitz; J Breuer
Journal:  Clin Res Cardiol       Date:  2006-01-16       Impact factor: 5.460

3.  Measurement of Aortic Valve Coaptation and Effective Height Using Echocardiography in Patients with Ventricular Septal Defects and Aortic Valve Prolapse.

Authors:  Satoru Iwashima; Hiroki Uchiyama; Takamichi Ishikawa; Kiyohiro Takigiku; Ken Takahashi; Manatomo Toyono; Nao Inoue; Masaki Nii
Journal:  Pediatr Cardiol       Date:  2017-01-21       Impact factor: 1.655

4.  Minimally invasive perventricular device closure of doubly committed sub-arterial ventricular septal defects: single center long-term follow-up results.

Authors:  Shu Zhang; Da Zhu; Qi An; Hong Tang; Dajiang Li; Ke Lin
Journal:  J Cardiothorac Surg       Date:  2015-09-15       Impact factor: 1.637

5.  A meta-analysis of perventricular device closure of doubly committed subarterial ventricular septal defects.

Authors:  Jiang-Shan Huang; Kai-Peng Sun; Shu-Ting Huang; Qiang Chen; Liang-Wan Chen; Yur-Ren Kuo
Journal:  J Cardiothorac Surg       Date:  2020-01-28       Impact factor: 1.637

6.  Transfemoral Occlusion of Doubly Committed Subarterial Ventricular Septal Defect Using the Amplatzer Duct Occluder-II in Children.

Authors:  Changqing Tang; Kaiyu Zhou; Shuran Shao; Xiaoliang Liu; Yifei Li; Yimin Hua; Chuan Wang
Journal:  Front Cardiovasc Med       Date:  2022-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.